The benefits, limitations and opportunities of preclinical models for neonatal drug development

  • Publication Date :
  • Publication Type : Journal Article
  • Author(s) : Sarah Campion, Amy Inselman, Belinda Hayes, Costanza Casiraghi, David Joseph, Fabrizio Facchinetti, Fabrizio Salomone, Georg Schmitt, Julia Hui, Karen Davis-Bruno, Karen Van Malderen, LaRonda Morford, Luc De Schaepdrijver, Lutz Wiesner, Stephanie Kourula, Suna Seo, Susan Laffan, Vijay Urmaliya, Connie Chen
  • Journal Name : Disease Models & Mechanisms

Increased research to improve preclinical models to inform the development of therapeutics for neonatal diseases is an area of great need. This article reviews five common neonatal diseases – bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, perinatal hypoxic–ischemic encephalopathy and neonatal sepsis – and the available in vivo, in vitro and in silico preclinical models for studying these diseases. Better understanding of the strengths and weaknesses of specialized neonatal disease models will help to improve their utility, may add to the understanding of the mode of action and efficacy of a therapeutic, and/or may improve the understanding of the disease pathology to aid in identification of new therapeutic targets. Although the diseases covered in this article are diverse and require specific approaches, several high-level, overarching key lessons can be learned by evaluating the strengths, weaknesses and gaps in the available models. This Review is intended to help guide current and future researchers toward successful development of therapeutics in these areas of high unmet medical need.


Read the full article here

Learn more about HESI's Developmental and Reproductive Toxicology (DART) Committee


Contact Us

Health and Environmental Sciences Institute (HESI)
Phone: +1-202-659-8404
Fax: +1-202-659-3859

740 15th Street NW, Suite 600
Washington, DC 20005

Stay Informed

Sign up for our monthly e-newsletter.